Ajanta Pharma Launches Acid Reflux Drug In US
New Delhi: Ajanta Pharma has launched generic omeprazole and sodium bicarbonate capsules, used in the treatment of acid reflux and ulcers, in the American market after receiving final approval from the US Food and Drug Administration (FDA).
The company has launched the product in the US through its wholly-owned subsidiary - Ajanta Pharma USA Inc, Ajanta Pharma said in a filing to the BSE.
The approval from the US health regulator (FDA) is for the capsules in the strengths of 20mg/1100 mg and 40 mg/1100 mg, it added.
The capsules are a generic version of Santarus Inc's Zegerid capsules.
The company has 26 abbreviated new drug applications (ANDAs), of which it has received final approvals for 11 and tentative nods for one, while 14 are under review with the US regulator, it added.
At 3:09 p.m., shares in Ajanta Pharma were trading 0.6 per cent lower at Rs 1,588.45 apiece on the BSE, whose benchmark Sensex index was down 0.13 per cent.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
